No Data
Capricor Therapeutics Is Maintained at Outperform by Oppenheimer
Capricor Therapeutics Price Target Raised to $15.00/Share From $14.00 by Oppenheimer
Oppenheimer Maintains Capricor Therapeutics(CAPR.US) With Buy Rating, Raises Target Price to $15
Oppenheimer analyst Leland Gershell maintains $Capricor Therapeutics(CAPR.US)$ with a buy rating, and adjusts the target price from $14 to $15.According to TipRanks data, the analyst has a success
H.C. Wainwright Maintains Capricor Therapeutics(CAPR.US) With Buy Rating, Maintains Target Price $40
H.C. Wainwright analyst Joseph Pantginis maintains $Capricor Therapeutics(CAPR.US)$ with a buy rating, and maintains the target price at $40.According to TipRanks data, the analyst has a success
HC Wainwright & Co. Reiterates Buy on Capricor Therapeutics, Maintains $40 Price Target
Capricor Therapeutics Analyst Ratings